WO2007071357A2 - Pharmaceutical composition comprising (e) -7- [4- (4-fluorophenyl) -6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin-5 -yl- (3r, 5s) -3, 5-dihydr0xyhept-6-en0ic acid - Google Patents
Pharmaceutical composition comprising (e) -7- [4- (4-fluorophenyl) -6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin-5 -yl- (3r, 5s) -3, 5-dihydr0xyhept-6-en0ic acid Download PDFInfo
- Publication number
- WO2007071357A2 WO2007071357A2 PCT/EP2006/012180 EP2006012180W WO2007071357A2 WO 2007071357 A2 WO2007071357 A2 WO 2007071357A2 EP 2006012180 W EP2006012180 W EP 2006012180W WO 2007071357 A2 WO2007071357 A2 WO 2007071357A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- isopropyl
- fluorophenyl
- pyrimidin
- methyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0620629A BRPI0620629B8 (en) | 2005-12-20 | 2006-12-18 | pharmaceutical composition, process for preparing a pharmaceutical composition and its use |
AU2006329006A AU2006329006B2 (en) | 2005-12-20 | 2006-12-18 | Pharmaceutical composition comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid |
EA200801447A EA015682B1 (en) | 2005-12-20 | 2006-12-18 | Pharmaceutical composition |
US12/158,413 US20090093499A1 (en) | 2005-12-20 | 2006-12-18 | Pharmaceutical composition |
EP06829701.9A EP1968593B1 (en) | 2005-12-20 | 2006-12-18 | Pharmaceutical composition comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl-(3r,5s)-3,5-dihydroxyhept-6-enoic acid |
CA2630704A CA2630704C (en) | 2005-12-20 | 2006-12-18 | Pharmaceutical composition |
JP2008546216A JP5235676B2 (en) | 2005-12-20 | 2006-12-18 | (E) -7- [4- (4-Fluorophenyl) -6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin-5-yl]-(3R, 5S) -3,5-dihydroxyhepta Pharmaceutical composition comprising 6-enoic acid |
CN2006800476115A CN101330919B (en) | 2005-12-20 | 2006-12-18 | Pharmaceutical composition including (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrim idin-5-yl]-(3R, 5S)-3,5-dihydroxyhept-6-enoic acid |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SIP200500344 | 2005-12-20 | ||
SI200500344 | 2005-12-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007071357A2 true WO2007071357A2 (en) | 2007-06-28 |
WO2007071357A3 WO2007071357A3 (en) | 2007-11-08 |
Family
ID=37866173
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2006/012180 WO2007071357A2 (en) | 2005-12-20 | 2006-12-18 | Pharmaceutical composition comprising (e) -7- [4- (4-fluorophenyl) -6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin-5 -yl- (3r, 5s) -3, 5-dihydr0xyhept-6-en0ic acid |
Country Status (9)
Country | Link |
---|---|
US (1) | US20090093499A1 (en) |
EP (1) | EP1968593B1 (en) |
JP (1) | JP5235676B2 (en) |
CN (1) | CN101330919B (en) |
AU (1) | AU2006329006B2 (en) |
BR (1) | BRPI0620629B8 (en) |
CA (1) | CA2630704C (en) |
EA (1) | EA015682B1 (en) |
WO (1) | WO2007071357A2 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009095934A1 (en) * | 2008-01-30 | 2009-08-06 | Lupin Limited | Modified release formulations of hmg coa reductase inhibitors |
EP2138165A1 (en) | 2008-06-27 | 2009-12-30 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical composition comprising a statin |
WO2009156173A1 (en) * | 2008-06-27 | 2009-12-30 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Pharmaceutical composition comprising a statin |
WO2010030201A2 (en) * | 2008-09-09 | 2010-03-18 | Zaklady Farmaceutyczne Polpharma Sa | Stable oral pharmaceutical composition containing a pharmaceutically acceptable salt of [(e)-7-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidine-5-yl] (3r, 5s) - 3,5 dihydroxyhept-6- enoic acid |
EP2233133A1 (en) | 2009-03-17 | 2010-09-29 | Sanovel Ilac Sanayi ve Ticaret A.S. | Stable Rosuvastatin Compositions |
US7994178B2 (en) | 2006-09-18 | 2011-08-09 | Teva Pharmaceutical Industries, Ltd. | Crystalline rosuvastatin calcium and compositions thereof for treatment of hyperlipidaemia |
RU2606592C1 (en) * | 2015-10-07 | 2017-01-10 | Открытое Акционерное Общество "Татхимфармпрепараты" | Pharmaceutical composition containing rosuvastatin calcium salt (versions) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2020417043A1 (en) * | 2019-12-31 | 2022-06-09 | Pfizer R&D Uk Limited | Stable immediate release tablet and capsule formulations of 1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0521471A1 (en) * | 1991-07-01 | 1993-01-07 | Shionogi Seiyaku Kabushiki Kaisha | Pyrimidine derivatives as HMG-CoA reductase inhibitors |
WO2002089788A2 (en) * | 2001-05-04 | 2002-11-14 | Sandoz Gmbh | Pharmaceutical compositions comprising a hmg-coa reductase inhibitor |
US6548513B1 (en) * | 2000-01-26 | 2003-04-15 | Astrazeneca Ab | Pharmaceutical compositions |
WO2003092729A1 (en) * | 2002-05-03 | 2003-11-13 | Hexal Ag | Stable pharmaceutical formulation for a combination of a statin and an ace inhibitor |
WO2004071403A2 (en) * | 2003-02-12 | 2004-08-26 | Lek Pharmaceuticals D.D. | Coated particles and pharmaceutical dosage forms |
WO2005040134A1 (en) * | 2003-10-22 | 2005-05-06 | Ranbaxy Laboratories Limited | Process for the preparation of amorphous rosuvastatin calcium |
WO2005077916A1 (en) * | 2004-01-19 | 2005-08-25 | Ranbaxy Laboratories Limited | Salts of hmg-coa reductase inhibitors and use thereof |
US20050187234A1 (en) * | 2003-12-02 | 2005-08-25 | Nina Finkelstein | Reference standard for characterization of rosuvastatin |
WO2005077917A1 (en) * | 2004-01-19 | 2005-08-25 | Ranbaxy Laboratories Limited | Amorphous salts of rosuvastatin |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0000710D0 (en) * | 1999-02-06 | 2000-03-08 | Zeneca Ltd | Drug combination |
US6399101B1 (en) * | 2000-03-30 | 2002-06-04 | Mova Pharmaceutical Corp. | Stable thyroid hormone preparations and method of making same |
IL157634A0 (en) * | 2001-03-13 | 2004-03-28 | Penwest Pharmaceuticals Co | Chronotherapeutic dosage forms containing glucocorticosteroid |
SE0101329D0 (en) * | 2001-04-12 | 2001-04-12 | Astrazeneca Ab | Pharmaceutical formulation |
JP2005526095A (en) * | 2002-03-20 | 2005-09-02 | エラン ファーマ インターナショナル,リミティド | Rapid dissolution dosage form with low friability |
AU2003225102A1 (en) * | 2002-04-23 | 2003-11-10 | Bristol-Myers Squibb Company | Modified-release vasopeptidase inhibitor formulation, combinations and method |
US8987322B2 (en) * | 2003-11-04 | 2015-03-24 | Circ Pharma Research And Development Limited | Pharmaceutical formulations for carrier-mediated transport statins and uses thereof |
-
2006
- 2006-12-18 EA EA200801447A patent/EA015682B1/en not_active IP Right Cessation
- 2006-12-18 AU AU2006329006A patent/AU2006329006B2/en not_active Ceased
- 2006-12-18 CA CA2630704A patent/CA2630704C/en not_active Expired - Fee Related
- 2006-12-18 WO PCT/EP2006/012180 patent/WO2007071357A2/en active Application Filing
- 2006-12-18 BR BRPI0620629A patent/BRPI0620629B8/en not_active IP Right Cessation
- 2006-12-18 EP EP06829701.9A patent/EP1968593B1/en not_active Not-in-force
- 2006-12-18 US US12/158,413 patent/US20090093499A1/en not_active Abandoned
- 2006-12-18 CN CN2006800476115A patent/CN101330919B/en not_active Expired - Fee Related
- 2006-12-18 JP JP2008546216A patent/JP5235676B2/en not_active Expired - Fee Related
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0521471A1 (en) * | 1991-07-01 | 1993-01-07 | Shionogi Seiyaku Kabushiki Kaisha | Pyrimidine derivatives as HMG-CoA reductase inhibitors |
US6548513B1 (en) * | 2000-01-26 | 2003-04-15 | Astrazeneca Ab | Pharmaceutical compositions |
WO2002089788A2 (en) * | 2001-05-04 | 2002-11-14 | Sandoz Gmbh | Pharmaceutical compositions comprising a hmg-coa reductase inhibitor |
WO2003092729A1 (en) * | 2002-05-03 | 2003-11-13 | Hexal Ag | Stable pharmaceutical formulation for a combination of a statin and an ace inhibitor |
WO2004071403A2 (en) * | 2003-02-12 | 2004-08-26 | Lek Pharmaceuticals D.D. | Coated particles and pharmaceutical dosage forms |
WO2005040134A1 (en) * | 2003-10-22 | 2005-05-06 | Ranbaxy Laboratories Limited | Process for the preparation of amorphous rosuvastatin calcium |
US20050187234A1 (en) * | 2003-12-02 | 2005-08-25 | Nina Finkelstein | Reference standard for characterization of rosuvastatin |
WO2005077916A1 (en) * | 2004-01-19 | 2005-08-25 | Ranbaxy Laboratories Limited | Salts of hmg-coa reductase inhibitors and use thereof |
WO2005077917A1 (en) * | 2004-01-19 | 2005-08-25 | Ranbaxy Laboratories Limited | Amorphous salts of rosuvastatin |
Non-Patent Citations (2)
Title |
---|
"Core Data Sheet Crestor(TM) Tablets"[Online] 17 June 2003 (2003-06-17), XP002449400 Retrieved from the Internet: URL:http://www.crestor.info/gUserFiles/CRESTOR_CDS_10_40_mg_FINAL_170603.pdf> [retrieved on 2007-09-05] * |
See also references of EP1968593A2 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7994178B2 (en) | 2006-09-18 | 2011-08-09 | Teva Pharmaceutical Industries, Ltd. | Crystalline rosuvastatin calcium and compositions thereof for treatment of hyperlipidaemia |
WO2009095934A1 (en) * | 2008-01-30 | 2009-08-06 | Lupin Limited | Modified release formulations of hmg coa reductase inhibitors |
EP2138165A1 (en) | 2008-06-27 | 2009-12-30 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical composition comprising a statin |
WO2009156173A1 (en) * | 2008-06-27 | 2009-12-30 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Pharmaceutical composition comprising a statin |
EA024554B1 (en) * | 2008-06-27 | 2016-09-30 | Крка, Товарна Здравил, Д.Д., Ново Место | Solid dosage form comprising rosuvastatin, and process for preparation thereof |
WO2010030201A2 (en) * | 2008-09-09 | 2010-03-18 | Zaklady Farmaceutyczne Polpharma Sa | Stable oral pharmaceutical composition containing a pharmaceutically acceptable salt of [(e)-7-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidine-5-yl] (3r, 5s) - 3,5 dihydroxyhept-6- enoic acid |
WO2010030201A3 (en) * | 2008-09-09 | 2010-07-22 | Zaklady Farmaceutyczne Polpharma Sa | Stable oral pharmaceutical composition containing a pharmaceutically acceptable salt of [(e)-7-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidine-5-yl] (3r, 5s) - 3,5 dihydroxyhept-6- enoic acid |
EP2233133A1 (en) | 2009-03-17 | 2010-09-29 | Sanovel Ilac Sanayi ve Ticaret A.S. | Stable Rosuvastatin Compositions |
RU2606592C1 (en) * | 2015-10-07 | 2017-01-10 | Открытое Акционерное Общество "Татхимфармпрепараты" | Pharmaceutical composition containing rosuvastatin calcium salt (versions) |
Also Published As
Publication number | Publication date |
---|---|
EP1968593A2 (en) | 2008-09-17 |
CN101330919B (en) | 2012-12-05 |
JP5235676B2 (en) | 2013-07-10 |
BRPI0620629B8 (en) | 2021-05-25 |
US20090093499A1 (en) | 2009-04-09 |
EA015682B1 (en) | 2011-10-31 |
AU2006329006A1 (en) | 2007-06-28 |
AU2006329006B2 (en) | 2013-02-28 |
EP1968593B1 (en) | 2017-08-23 |
CN101330919A (en) | 2008-12-24 |
JP2009519985A (en) | 2009-05-21 |
BRPI0620629B1 (en) | 2020-01-14 |
CA2630704A1 (en) | 2007-06-28 |
BRPI0620629A2 (en) | 2011-11-16 |
WO2007071357A3 (en) | 2007-11-08 |
EA200801447A1 (en) | 2008-12-30 |
CA2630704C (en) | 2014-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI111806B (en) | Pharmaceutical compositions | |
CA2630704C (en) | Pharmaceutical composition | |
KR20150079454A (en) | Composite formulation for oral administration comprising ezetimibe and rosuvastatin | |
CA2651138C (en) | Pharmaceutical composition | |
JP2018154596A (en) | Azilsartan-containing solid pharmaceutical composition | |
KR102517765B1 (en) | Pharmaceutical composition comprising rosuvastatin and ezetimibe and method for preparing the same | |
EP2233133B1 (en) | Stable Rosuvastatin Compositions | |
JP2009519985A5 (en) | ||
US20070298108A1 (en) | Pharmaceutical Formulation | |
WO2011099573A1 (en) | Extended release preparation | |
JP2017095441A (en) | Azilsartan-containing pharmaceutical compositions, stabilization method of azilsartan in pharmaceutical compositions, and stabilizer of azilsartan | |
JP6750785B2 (en) | Stable rosuvastatin calcium tablets | |
MX2008008192A (en) | Pharmaceutical composition comprising (e) -7- [4- (4-fluorophenyl) -6-isopropyl-2- [methyl (methylsulfonyl) amino]pyrimidin-5 -yl- (3r, 5s) -3, 5-dihydr0xyhept-6-en0ic acid | |
JP6765473B2 (en) | Olmesartan prodrug formulation | |
JPWO2018021416A1 (en) | Methotrexate-containing film-coated tablets | |
JP6573098B2 (en) | Stable rosuvastatin calcium tablets |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680047611.5 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2630704 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008546216 Country of ref document: JP Ref document number: 2006329006 Country of ref document: AU Ref document number: 3076/CHENP/2008 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2008/008192 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200801447 Country of ref document: EA |
|
ENP | Entry into the national phase |
Ref document number: 2006329006 Country of ref document: AU Date of ref document: 20061218 Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2006829701 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006829701 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2006329006 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2006829701 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12158413 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0620629 Country of ref document: BR Kind code of ref document: A2 Effective date: 20080620 |